The myelodysplastic syndromes (MDS) are a heterogeneous collection of clonal hematopoietic malignancies that compromise a large subgroup of the myeloid neoplasms and collectively are the most common acquired adult bone marrow failure syndromes. Currently, only a few agents are approved for the treatment of MDS. The heterogeneity of MDS as a disease group is likely to be a strong contributor to this slow progress but recent developments in mouse models and molecular characterization of MDS are improving diagnostic accuracy, providing insights into pathogenesis, and refining our knowledge the field. With the advent of these developments, appropriately chosen therapeutics or even targeted agents may be able to improve patient outcomes in the future.
The objective of this research topic is to bring together the scientific community to extend the current level of knowledge in the MDS field with manuscripts encompassing recent advances concerning relevant models (xenografts and genetically engineered) and the utility of single cell sequencing to better understand the disease heterogeneity in MDS. We will learn lessons from precursor states as well as from the pediatric clinics for those with germline MDS. Lastly, we will review current efficacy of novel therapeutics and promising combination approaches to further improve outcomes in the treatment of patients with MDS. We welcome the submission of Original Research, Review and Clinical Trial articles.
The myelodysplastic syndromes (MDS) are a heterogeneous collection of clonal hematopoietic malignancies that compromise a large subgroup of the myeloid neoplasms and collectively are the most common acquired adult bone marrow failure syndromes. Currently, only a few agents are approved for the treatment of MDS. The heterogeneity of MDS as a disease group is likely to be a strong contributor to this slow progress but recent developments in mouse models and molecular characterization of MDS are improving diagnostic accuracy, providing insights into pathogenesis, and refining our knowledge the field. With the advent of these developments, appropriately chosen therapeutics or even targeted agents may be able to improve patient outcomes in the future.
The objective of this research topic is to bring together the scientific community to extend the current level of knowledge in the MDS field with manuscripts encompassing recent advances concerning relevant models (xenografts and genetically engineered) and the utility of single cell sequencing to better understand the disease heterogeneity in MDS. We will learn lessons from precursor states as well as from the pediatric clinics for those with germline MDS. Lastly, we will review current efficacy of novel therapeutics and promising combination approaches to further improve outcomes in the treatment of patients with MDS. We welcome the submission of Original Research, Review and Clinical Trial articles.
